CYTOSORBENTS CORP (CTSO) Stock Fundamental Analysis

NASDAQ:CTSO • US23283X2062

0.6402 USD
-0.01 (-1.34%)
Last: Feb 20, 2026, 08:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

CTSO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. CTSO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CTSO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CTSO had negative earnings in the past year.
  • CTSO had a negative operating cash flow in the past year.
  • In the past 5 years CTSO always reported negative net income.
  • CTSO had a negative operating cash flow in each of the past 5 years.
CTSO Yearly Net Income VS EBIT VS OCF VS FCFCTSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • CTSO's Return On Assets of -23.14% is in line compared to the rest of the industry. CTSO outperforms 50.81% of its industry peers.
  • With a Return On Equity value of -117.35%, CTSO is not doing good in the industry: 64.32% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -23.14%
ROE -117.35%
ROIC N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
CTSO Yearly ROA, ROE, ROICCTSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • The Gross Margin of CTSO (77.02%) is better than 89.19% of its industry peers.
  • CTSO's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CTSO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
CTSO Yearly Profit, Operating, Gross MarginsCTSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CTSO has more shares outstanding
  • Compared to 5 years ago, CTSO has more shares outstanding
  • CTSO has a worse debt/assets ratio than last year.
CTSO Yearly Shares OutstandingCTSO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CTSO Yearly Total Debt VS Total AssetsCTSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -8.71, we must say that CTSO is in the distress zone and has some risk of bankruptcy.
  • CTSO has a worse Altman-Z score (-8.71) than 74.05% of its industry peers.
  • A Debt/Equity ratio of 1.61 is on the high side and indicates that CTSO has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.61, CTSO is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Altman-Z -8.71
ROIC/WACCN/A
WACC11.05%
CTSO Yearly LT Debt VS Equity VS FCFCTSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • CTSO has a Current Ratio of 2.11. This indicates that CTSO is financially healthy and has no problem in meeting its short term obligations.
  • CTSO has a Current ratio (2.11) which is comparable to the rest of the industry.
  • CTSO has a Quick Ratio of 1.71. This is a normal value and indicates that CTSO is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.71, CTSO is in line with its industry, outperforming 46.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 1.71
CTSO Yearly Current Assets VS Current LiabilitesCTSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 51.35% over the past year.
  • Looking at the last year, CTSO shows a decrease in Revenue. The Revenue has decreased by -8.97% in the last year.
  • CTSO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.36% yearly.
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%1.01%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.52% on average over the next years. This is a very strong growth
  • CTSO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.86% yearly.
EPS Next Y55.26%
EPS Next 2Y-173.17%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue Next Year-3.8%
Revenue Next 2Y2.36%
Revenue Next 3Y8.04%
Revenue Next 5Y26.87%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTSO Yearly Revenue VS EstimatesCTSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CTSO Yearly EPS VS EstimatesCTSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CTSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTSO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTSO Price Earnings VS Forward Price EarningsCTSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTSO Per share dataCTSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • CTSO's earnings are expected to grow with 22.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-173.17%
EPS Next 3Y22.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CTSO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYTOSORBENTS CORP

NASDAQ:CTSO (2/20/2026, 8:26:06 PM)

0.6402

-0.01 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-02
Earnings (Next)03-11
Inst Owners26.2%
Inst Owner Change2.3%
Ins Owners9.21%
Ins Owner Change1.36%
Market Cap40.20M
Revenue(TTM)34.35M
Net Income(TTM)-10.59M
Analysts80
Price Target5.36 (737.24%)
Short Float %3.84%
Short Ratio19.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)76.89%
Min EPS beat(2)-5.03%
Max EPS beat(2)158.82%
EPS beat(4)2
Avg EPS beat(4)27.26%
Min EPS beat(4)-116.73%
Max EPS beat(4)158.82%
EPS beat(8)6
Avg EPS beat(8)21.99%
EPS beat(12)7
Avg EPS beat(12)13.46%
EPS beat(16)7
Avg EPS beat(16)-7.04%
Revenue beat(2)1
Avg Revenue beat(2)-2.61%
Min Revenue beat(2)-7.32%
Max Revenue beat(2)2.1%
Revenue beat(4)1
Avg Revenue beat(4)-5.35%
Min Revenue beat(4)-11.18%
Max Revenue beat(4)2.1%
Revenue beat(8)2
Avg Revenue beat(8)-5.15%
Revenue beat(12)4
Avg Revenue beat(12)-4.39%
Revenue beat(16)5
Avg Revenue beat(16)-5.31%
PT rev (1m)-2.33%
PT rev (3m)5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.53%
Revenue NQ rev (1m)-2.71%
Revenue NQ rev (3m)-11.51%
Revenue NY rev (1m)-0.62%
Revenue NY rev (3m)-4.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.17
P/FCF N/A
P/OCF N/A
P/B 4.46
P/tB 7.41
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-2.84
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.55
BVpS0.14
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.14%
ROE -117.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.02%
FCFM N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.94%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 1.71
Altman-Z -8.71
F-Score4
WACC11.05%
ROIC/WACCN/A
Cap/Depr(3y)280.25%
Cap/Depr(5y)336.32%
Cap/Sales(3y)7.84%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y55.26%
EPS Next 2Y-173.17%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%1.01%
Revenue Next Year-3.8%
Revenue Next 2Y2.36%
Revenue Next 3Y8.04%
Revenue Next 5Y26.87%
EBIT growth 1Y32.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.1%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.53%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOSORBENTS CORP / CTSO FAQ

What is the fundamental rating for CTSO stock?

ChartMill assigns a fundamental rating of 2 / 10 to CTSO.


What is the valuation status of CYTOSORBENTS CORP (CTSO) stock?

ChartMill assigns a valuation rating of 1 / 10 to CYTOSORBENTS CORP (CTSO). This can be considered as Overvalued.


How profitable is CYTOSORBENTS CORP (CTSO) stock?

CYTOSORBENTS CORP (CTSO) has a profitability rating of 1 / 10.


Can you provide the financial health for CTSO stock?

The financial health rating of CYTOSORBENTS CORP (CTSO) is 2 / 10.